Mogamulizumab (CCR4/CD194) Antibody, Monoclonal

AMG-761,KW-0761

Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and S?zary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions 8.On August 8 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab injection (also known as Poteligeo) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S?zary syndrome (SS) after at least one prior systemic therapy 7.Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT (?) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma 2.

PBS buffer pH7.5

batch dependent

Unconjugated

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

Humanized / CCR4/CD194 [Homo sapiens]

homo sapiens

>95%

Drug Analogues

CHO cells

Optimal dilutions for each application to be determined by the researcher.